Changes in Circulating ProAMH and Total AMH during Healthy Pregnancy and Post-Partum: A Longitudinal Study.
Circulating Anti-Müllerian hormone (AMH) is derived from the gonads, and is a mixture of the prohormone (proAMH), which does not bind to AMH receptors, and receptor-competent AMH. The functions of a hormone are partially defined by the factors that control its levels. Ovarian reserve accounts for 55~75% of the woman-to-woman variation in AMH level, leaving over 25% of the biological variation to be explained. Pregnancy has been reported to decrease circulating AMH levels, but the observations are inconsistent, with the effect of pregnancy on the bioactivity of AMH being unknown. We have therefore undertaken a longitudinal study of circulating proAMH and total AMH during pregnancy. Serum samples were drawn at 6-8 gestational time-points (first trimester to post-partum) from 25 healthy women with prior uneventful pregnancies. The total AMH and proAMH levels were measured at each time-point using ELISA. The level of circulating total AMH progressively decreased during pregnancy, in all women (p<0.001). On average, the percentage decline between the first trimester and 36-39 weeks' gestation was 61.5%, with a standard deviation of 13.0% (range 30.4-81.2%). The percentage decline in total AMH levels associated with maternal age (R = -0.53, p = 0.024), but not with the women's first trimester AMH level. The postpartum total AMH levels showed no consistent relationship to the woman's first trimester values (range 31-273%). This raises the possibility that a fundamental determinant of circulating AMH levels is reset during pregnancy. The ratio of proAMH to total AMH levels exhibited little or no variation during pregnancy, indicating that the control of the cleavage/activation of AMH is distinct from the mechanisms that control the total level of AMH.
Department of Anatomy, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand.
Michael W
MW
Pankhurst
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.|LifeQuest Centre for Reproductive Medicine, Toronto, Canada.
Christine A
CA
Clark
LifeQuest Centre for Reproductive Medicine, Toronto, Canada.|Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, Hospital for Sick Children, Toronto, Canada.
Judith
J
Zarek
LifeQuest Centre for Reproductive Medicine, Toronto, Canada.
Carl A
CA
Laskin
Department of Anatomy, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand.
Ian S
http://orcid.org/0000-0002-8365-6341
IS
McLennan
D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008423:Maternal Age; D049590:Postpartum Period / Q000097:blood*; D011247:Pregnancy; D011264:Pregnancy Trimesters; D011498:Protein Precursors / Q000097:blood; D055815:Young Adult
D011498:Protein Precursors; D054304:Anti-Mullerian Hormone